Biolase Stock Price, News & Analysis (NASDAQ:BIOL)

$0.42 -0.01 (-2.33 %)
(As of 12/15/2017 01:13 AM ET)
Previous Close$0.43
Today's Range$0.41 - $0.43
52-Week Range$0.28 - $1.90
Volume55,700 shs
Average Volume165,783 shs
Market Capitalization$31.84 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3

About Biolase (NASDAQ:BIOL)

Biolase logoBIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOL
CUSIPN/A
Phone949-361-1200

Debt

Debt-to-Equity RatioN/A
Current Ratio1.98%
Quick Ratio1.04%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$51.81 million
Price / Sales0.62
Cash FlowN/A
Price / CashN/A
Book Value$0.33 per share
Price / Book1.27

Profitability

Trailing EPS($0.31)
Net Income$-15,370,000.00
Net Margins-36.28%
Return on Equity-74.51%
Return on Assets-40.81%

Miscellaneous

Employees225
Outstanding Shares76,020,000

Biolase (NASDAQ:BIOL) Frequently Asked Questions

What is Biolase's stock symbol?

Biolase trades on the NASDAQ under the ticker symbol "BIOL."

How were Biolase's earnings last quarter?

Biolase, Inc. (NASDAQ:BIOL) posted its quarterly earnings data on Monday, May, 9th. The medical technology company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.04. The medical technology company earned $11 million during the quarter, compared to analysts' expectations of $11.90 million. Biolase had a negative return on equity of 74.51% and a negative net margin of 36.28%. View Biolase's Earnings History.

When will Biolase make its next earnings announcement?

Biolase is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Biolase.

Where is Biolase's stock going? Where will Biolase's stock price be in 2017?

1 brokers have issued 1-year price objectives for Biolase's shares. Their forecasts range from $2.50 to $2.50. On average, they anticipate Biolase's stock price to reach $2.50 in the next year. View Analyst Ratings for Biolase.

Who are some of Biolase's key competitors?

Who are Biolase's key executives?

Biolase's management team includes the folowing people:

  • Jonathan T. Lord M.D., Chairman of the Board (Age 61)
  • Harold C. Flynn Jr., President, Chief Executive Officer (Age 50)
  • John R. Beaver, Chief Financial Officer, Senior Vice President (Age 53)
  • Brendan O'Connell, Vice President - Finance and Corporate Controller (Age 38)
  • Holger Arens, Vice President, Managing Director of Europe, the Middle East and Africa (Age 54)
  • James D. Surek, Vice President - Sales, Americas
  • Michael Roux, Vice President of Marketing
  • Matthew Wilson, Vice President of Human Resources
  • Samuel B. Low, Vice President - Dental and Clinical Affairs, Chief Dental Officer
  • George W. Bickerstaff III, Director (Age 61)

How do I buy Biolase stock?

Shares of Biolase can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biolase's stock price today?

One share of Biolase stock can currently be purchased for approximately $0.42.

How big of a company is Biolase?

Biolase has a market capitalization of $31.84 million and generates $51.81 million in revenue each year. The medical technology company earns $-15,370,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. Biolase employs 225 workers across the globe.

How can I contact Biolase?

Biolase's mailing address is 4 CROMWELL, IRVINE CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]


MarketBeat Community Rating for Biolase (BIOL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about Biolase and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biolase (NASDAQ:BIOL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.50$2.50$2.50$2.50
Price Target Upside: 96.85% upside96.85% upside96.85% upside96.85% upside

Biolase (NASDAQ:BIOL) Consensus Price Target History

Price Target History for Biolase (NASDAQ:BIOL)

Biolase (NASDAQ:BIOL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/25/2017Singular ResearchInitiated CoverageBuy$2.50LowView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Biolase (NASDAQ:BIOL) Earnings History and Estimates Chart

Earnings by Quarter for Biolase (NASDAQ:BIOL)

Biolase (NASDAQ BIOL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($0.04)N/AView Earnings Details
8/7/2017Q2 2017($0.02)($0.06)$12.61 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.03)($0.06)$10.87 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.02($0.06)$13.76 millionViewListenView Earnings Details
11/8/2016Q316($0.02)($0.05)$12.40 million$13.20 millionViewListenView Earnings Details
5/9/2016Q116($0.03)($0.07)$11.90 million$11.00 millionViewN/AView Earnings Details
3/9/2016Q415($0.09)($0.04)$13.90 million$14.50 millionViewN/AView Earnings Details
11/4/2015Q315($0.08)($0.09)$1.50 million$11.20 millionViewN/AView Earnings Details
11/4/2014Q314($0.09)($0.08)$11.70 million$12.70 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.17)$12.97 million$10.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.11)$13.29 million$11.50 millionViewN/AView Earnings Details
3/5/2014Q413($0.04)($0.04)$15.67 million$15.20 millionViewN/AView Earnings Details
11/5/2013Q313($0.05)($0.10)$16.42 million$12.30 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.04)($0.06)$15.69 million$14.20 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.06)$14.48 million$14.60 millionViewN/AView Earnings Details
3/6/2013Q4 2012$0.05$18.03 million$19.10 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Biolase (NASDAQ:BIOL) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Biolase (NASDAQ:BIOL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biolase (NASDAQ BIOL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.10%
Institutional Ownership Percentage: 38.86%
Insider Trades by Quarter for Biolase (NASDAQ:BIOL)
Institutional Ownership by Quarter for Biolase (NASDAQ:BIOL)

Biolase (NASDAQ BIOL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/5/2017Larry N FeinbergMajor ShareholderBuy12,545,615$0.43$5,394,614.45View SEC Filing  
2/18/2016Jack W SchulerMajor ShareholderBuy500$0.80$400.00View SEC Filing  
2/17/2016Jack W SchulerMajor ShareholderBuy4,100$0.80$3,280.00View SEC Filing  
2/12/2016Jack W SchulerMajor ShareholderBuy19,080$0.76$14,500.80View SEC Filing  
2/10/2016Jack W SchulerMajor ShareholderBuy67,213$0.78$52,426.14View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy1,400$0.80$1,120.00View SEC Filing  
1/22/2016Jack W SchulerMajor ShareholderBuy6,670$0.78$5,202.60View SEC Filing  
1/20/2016Jack W SchulerMajor ShareholderBuy24,200$0.75$18,150.00View SEC Filing  
12/28/2015Jack W SchulerMajor ShareholderBuy18,350$0.79$14,496.50View SEC Filing  
12/24/2015Jack W SchulerMajor ShareholderBuy41,900$0.76$31,844.00View SEC Filing  
12/22/2015Jack W SchulerMajor ShareholderBuy87,200$0.74$64,528.00View SEC Filing  
12/21/2015Jack W SchulerMajor ShareholderBuy127,892$0.73$93,361.16View SEC Filing  
12/17/2015Jack W SchulerMajor ShareholderBuy34,158$0.70$23,910.60View SEC Filing  
11/11/2015Larry N FeinbergMajor ShareholderBuy54,800$0.79$43,292.00View SEC Filing  
11/10/2015Paul N ClarkDirectorBuy134,579$0.75$100,934.25View SEC Filing  
9/24/2015David C DreyerCFOBuy5,000$1.20$6,000.00View SEC Filing  
9/22/2015David C DreyerCFOBuy5,000$1.37$6,850.00View SEC Filing  
9/17/2015David C DreyerCFOBuy10,000$1.45$14,500.00View SEC Filing  
11/3/2014Jeffrey M NugentCEOBuy40,465$2.39$96,711.35View SEC Filing  
11/3/2014Jonathan T Md LordDirectorBuy101,163$2.39$241,779.57View SEC Filing  
11/3/2014Larry N FeinbergMajor ShareholderBuy2,067,979$2.39$4,942,469.81View SEC Filing  
7/22/2014Alexander K ArrowCOOBuy7,812$1.92$14,999.04View SEC Filing  
7/22/2014Frederick D FurryCFOBuy13,020$1.92$24,998.40View SEC Filing  
7/22/2014Jeffrey M NugentCEOBuy52,083$1.92$99,999.36View SEC Filing  
7/22/2014Paul N ClarkDirectorBuy520,833$1.92$999,999.36View SEC Filing  
7/18/2014Larry N FeinbergMajor ShareholderBuy2,270,836$1.92$4,360,005.12View SEC Filing  
2/12/2014Larry N FeinbergMajor ShareholderBuy2,035,033$2.57$5,230,034.81View SEC Filing  
1/31/2014Larry Feinbergmajor shareholderBuy30,798$2.45$75,455.10View SEC Filing  
12/19/2013Larry Feinbergmajor shareholderBuy340,000$1.80$612,000.00View SEC Filing  
12/17/2013Larry Feinbergmajor shareholderBuy150,400$1.87$281,248.00View SEC Filing  
8/23/2012Frederick D FurryCFOBuy5,075$1.64$8,323.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biolase (NASDAQ BIOL) News Headlines

Source:
DateHeadline
ETFs with exposure to BIOLASE, Inc. : December 11, 2017ETFs with exposure to BIOLASE, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:43 PM
Critical Analysis: Mindray Medical International (MR) versus Biolase (BIOL)Critical Analysis: Mindray Medical International (MR) versus Biolase (BIOL)
www.americanbankingnews.com - December 7 at 3:32 AM
Biolase, Inc. (BIOL) Major Shareholder Larry N. Feinberg Purchases 12,545,615 SharesBiolase, Inc. (BIOL) Major Shareholder Larry N. Feinberg Purchases 12,545,615 Shares
www.americanbankingnews.com - December 6 at 5:22 PM
Zacks: Biolase, Inc. (BIOL) Given Average Rating of "Strong Buy" by AnalystsZacks: Biolase, Inc. (BIOL) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 2 at 11:30 PM
ETFs with exposure to BIOLASE, Inc. : December 1, 2017ETFs with exposure to BIOLASE, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 4:27 PM
BRIEF-BIOLASE Announces Expiration Of Rights OfferingBRIEF-BIOLASE Announces Expiration Of Rights Offering
www.reuters.com - November 30 at 3:44 PM
BIOLASE Announces Expiration of Rights OfferingBIOLASE Announces Expiration of Rights Offering
finance.yahoo.com - November 30 at 9:12 AM
Financial Comparison: Biolase (BIOL) and Synergetics USA (SURG)Financial Comparison: Biolase (BIOL) and Synergetics USA (SURG)
www.americanbankingnews.com - November 28 at 1:08 AM
BIOLASE to Conduct Demos of Portable Waterlase Express™ All-Tissue Laser System at Greater New York Dental MeetingBIOLASE to Conduct Demos of Portable Waterlase Express™ All-Tissue Laser System at Greater New York Dental Meeting
finance.yahoo.com - November 22 at 5:15 PM
ETFs with exposure to BIOLASE, Inc. : November 20, 2017ETFs with exposure to BIOLASE, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 3:23 PM
BIOLASE to Present at the LD Micro 10th Annual Main Event ConferenceBIOLASE to Present at the LD Micro 10th Annual Main Event Conference
finance.yahoo.com - November 17 at 8:42 AM
BIOLASE to Present at the Singular Research Best of the Uncovered 12th Annual Conference 2017BIOLASE to Present at the Singular Research Best of the Uncovered 12th Annual Conference 2017
finance.yahoo.com - November 16 at 9:33 AM
Biolase (BIOL) Commences Rights OfferingBiolase (BIOL) Commences Rights Offering
www.streetinsider.com - November 11 at 4:25 PM
BIOLASE Announces Commencement of Rights OfferingBIOLASE Announces Commencement of Rights Offering
finance.yahoo.com - November 9 at 5:41 PM
ETFs with exposure to BIOLASE, Inc. : November 9, 2017ETFs with exposure to BIOLASE, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 5:41 PM
BIOLASE, Inc. :BIOL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017BIOLASE, Inc. :BIOL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 5:09 PM
BIOLASE Announces Terms of Rights OfferingBIOLASE Announces Terms of Rights Offering
finance.yahoo.com - November 3 at 8:33 AM
Edited Transcript of BIOL earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of BIOL earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 5:12 PM
Biolase reports 3Q lossBiolase reports 3Q loss
finance.yahoo.com - November 1 at 10:12 PM
BIOLASE Reports 2017 Third Quarter and Nine-Month ResultsBIOLASE Reports 2017 Third Quarter and Nine-Month Results
finance.yahoo.com - November 1 at 5:11 PM
BIOLASE Appoints Richard B. Lanman to Board of DirectorsBIOLASE Appoints Richard B. Lanman to Board of Directors
finance.yahoo.com - October 31 at 5:41 PM
BRIEF-Biolase announces record date for previously announced proposed rights offeringBRIEF-Biolase announces record date for previously announced proposed rights offering
www.reuters.com - October 31 at 3:58 AM
BIOLASE Announces Record Date for Previously Announced Proposed Rights OfferingBIOLASE Announces Record Date for Previously Announced Proposed Rights Offering
finance.yahoo.com - October 30 at 5:35 PM
ETFs with exposure to BIOLASE, Inc. : October 30, 2017ETFs with exposure to BIOLASE, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 5:35 PM
Biolase, Inc. (BIOL) Set to Announce Quarterly Earnings on MondayBiolase, Inc. (BIOL) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Biolase (BIOL) versus IRIDEX Corporation (IRIX) Head to Head ContrastBiolase (BIOL) versus IRIDEX Corporation (IRIX) Head to Head Contrast
www.americanbankingnews.com - October 28 at 3:32 PM
BIOLASE® to Host 2017 Third Quarter Financial Results Conference Call on November 1BIOLASE® to Host 2017 Third Quarter Financial Results Conference Call on November 1
finance.yahoo.com - October 25 at 5:55 PM
GLOBAL DENTAL IMAGING MARKET FORECAST 2017-2025GLOBAL DENTAL IMAGING MARKET FORECAST 2017-2025
www.bizjournals.com - October 23 at 10:31 PM
Dental Surgical Equipment Market, 2024Dental Surgical Equipment Market, 2024
www.finanznachrichten.de - October 20 at 3:07 AM
ETFs with exposure to BIOLASE, Inc. : October 12, 2017ETFs with exposure to BIOLASE, Inc. : October 12, 2017
finance.yahoo.com - October 12 at 5:20 PM
Global Dental Market Analysis & Companies Dental Sales & Strategy Report 2017 - Projections to 2024Global Dental Market Analysis & Companies Dental Sales & Strategy Report 2017 - Projections to 2024
www.prnewswire.com - October 10 at 5:50 PM
Global Dental Market Analysis & Companies Dental Sales & Strategy Report 2017 - Projections to 2024Global Dental Market Analysis & Companies Dental Sales & Strategy Report 2017 - Projections to 2024
www.prnewswire.com - October 10 at 5:50 PM
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - October 5 at 8:00 AM
Should You Be Holding BIOLASE Inc (BIOL) Right Now?Should You Be Holding BIOLASE Inc (BIOL) Right Now?
finance.yahoo.com - October 3 at 2:03 AM
BIOLASE Announces Plans for Rights Offering to Stockholders - Business Wire (press release)BIOLASE Announces Plans for Rights Offering to Stockholders - Business Wire (press release)
www.businesswire.com - September 30 at 12:43 AM
BIOLASE Announces Plans for Rights Offering to StockholdersBIOLASE Announces Plans for Rights Offering to Stockholders
www.businesswire.com - September 29 at 2:40 PM
BRIEF-BIOLASE ‍expects about $8 mln to $12 mln for rights offering to stockholdersBRIEF-BIOLASE ‍expects about $8 mln to $12 mln for rights offering to stockholders
www.reuters.com - September 29 at 2:40 PM
Financial Contrast: Biolase (BIOL) and Its RivalsFinancial Contrast: Biolase (BIOL) and Its Rivals
www.americanbankingnews.com - September 26 at 4:28 PM
ETFs with exposure to BIOLASE, Inc. : September 6, 2017ETFs with exposure to BIOLASE, Inc. : September 6, 2017
finance.yahoo.com - September 5 at 11:15 PM
BIOLASE Names Jonathan T. Lord Chairman of the BoardBIOLASE Names Jonathan T. Lord Chairman of the Board
finance.yahoo.com - September 5 at 6:10 PM
LeMaitre Vascular (LMAT) and Biolase (BIOL) Head-To-Head ReviewLeMaitre Vascular (LMAT) and Biolase (BIOL) Head-To-Head Review
www.americanbankingnews.com - September 2 at 4:10 PM
ETFs with exposure to BIOLASE, Inc. : August 25, 2017ETFs with exposure to BIOLASE, Inc. : August 25, 2017
finance.yahoo.com - August 25 at 6:18 PM
Globsl $10 Billion Dental Diagnostics & Surgical Equipments Products Markets, 2022Globsl $10 Billion Dental Diagnostics & Surgical Equipments Products Markets, 2022
www.finanznachrichten.de - August 17 at 5:55 PM
BIOLASE, Inc. :BIOL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017BIOLASE, Inc. :BIOL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 16 at 5:05 PM
Global Dental Diagnostics & Surgical Equipments Market, Company Analysis & Forecast to 2024Global Dental Diagnostics & Surgical Equipments Market, Company Analysis & Forecast to 2024
www.prnewswire.com - August 14 at 9:59 PM
Contrasting Dextera Surgical (DXTR) and Biolase (NASDAQ:BIOL)Contrasting Dextera Surgical (DXTR) and Biolase (NASDAQ:BIOL)
www.americanbankingnews.com - August 11 at 3:08 PM
Edited Transcript of BIOL earnings conference call or presentation 7-Aug-17 8:30pm GMTEdited Transcript of BIOL earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 9:42 PM
ETFs with exposure to BIOLASE, Inc. : August 8, 2017ETFs with exposure to BIOLASE, Inc. : August 8, 2017
finance.yahoo.com - August 8 at 4:20 PM
Biolase, Inc. (BIOL) Releases  Earnings Results, Misses Estimates By $0.04 EPSBiolase, Inc. (BIOL) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - August 8 at 12:28 PM
Biolase reports 2Q lossBiolase reports 2Q loss
finance.yahoo.com - August 7 at 10:05 PM

SEC Filings

Biolase (NASDAQ:BIOL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biolase (NASDAQ:BIOL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biolase (NASDAQ BIOL) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.